{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:00:57Z","timestamp":1794258057505,"version":"4.9.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.lungcan.2022.06.012","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T02:31:47Z","timestamp":1655951507000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial"],"prefix":"10.1016","volume":"170","author":[{"given":"Fenneke","family":"Zwierenga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"van Veggel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Jeroen N.","family":"Hiltermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitta I.","family":"Hiddinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie B.M.","family":"Hijmering Kappelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arja","family":"ter Elst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayed M.S.","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cor","family":"van der Leest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianus J.","family":"de Langen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthonie J.","family":"van der Wekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.lungcan.2022.06.012_b0005","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA - J. Am. Med. Assoc."},{"issue":"1","key":"10.1016\/j.lungcan.2022.06.012_b0010","doi-asserted-by":"crossref","first-page":"d685","DOI":"10.2741\/Normano","article-title":"The role of EGF-related peptides in tumor growth","volume":"6","author":"Normanno","year":"2001","journal-title":"Front. Biosci."},{"key":"10.1016\/j.lungcan.2022.06.012_b0015","article-title":"Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer","author":"Kosaka","year":"2004","journal-title":"Biol. Clin. Implic."},{"issue":"21","key":"10.1016\/j.lungcan.2022.06.012_b0020","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non\u2013Small-Cell Lung Cancer to Gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2022.06.012_b0025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.lungcan.2022.06.012_b0030","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: Prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2022.06.012_b0035","doi-asserted-by":"crossref","unstructured":"J.P. Robichaux, X. Le, R.S.K. Vijayan, J.K. Hicks, S. Heeke, Y.Y. Elamin, H.Y. Lin, H. Udagawa, F. Skoulidis, H. Tran, S. Varghese, J. He, F. Zhang, M.B. Nilsson, L. Hu, A. Poteete, W. Rinsurongkawong, X. Zhang, C. Ren, X. Liu, L. Hong, J. Zhang, L. Diao, R. Madison, A.B. Schrock, J. Saam, V. Raymond, B. Fang, J. Wang, M.J. Ha, J.B. Cross, J.E. Gray, J. v. Heymach, Structure-based classification predicts drug response in EGFR-mutant NSCLC, Nature. 597 (2021) 732\u2013737. doi:10.1038\/s41586-021-03898-1.","DOI":"10.1038\/s41586-021-03898-1"},{"key":"10.1016\/j.lungcan.2022.06.012_b0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring egfr exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2022.06.012_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102990","article-title":"New therapeutic approaches to overcoming resistant EGFR exon 20 alterations","volume":"151","author":"Li","year":"2020","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"10.1016\/j.lungcan.2022.06.012_b0050","article-title":"EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors","volume":"1","author":"Vasconcelos","year":"2020","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.lungcan.2022.06.012_b0055","doi-asserted-by":"crossref","unstructured":"H. Yasuda, E. Park, C.H. Yun, N.J. Sng, A.R. Lucena-Araujo, W.L. Yeo, M.S. Huberman, D.W. Cohen, S. Nakayama, K. Ishioka, N. Yamaguchi, M. Hanna, G.R. Oxnard, C.S. Lathan, T. Moran, L. v. Sequist, J.E. Chaft, G.J. Riely, M.E. Arcila, R.A. Soo, M. Meyerson, M.J. Eck, S.S. Kobayashi, D.B. Costa, Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer, Science Translational Medicine. 5 (2013). doi:10.1126\/scitranslmed.3007205.","DOI":"10.1126\/scitranslmed.3007205"},{"issue":"7","key":"10.1016\/j.lungcan.2022.06.012_b0060","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.21037\/jtd.2018.07.61","article-title":"A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group","volume":"10","author":"Jiang","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.lungcan.2022.06.012_b0065","doi-asserted-by":"crossref","unstructured":"T. Hirano, H. Yasuda, T. Tani, J. Hamamoto, A. Oashi, K. Ishioka, D. Arai, S. Nukaga, M. Miyawaki, I. Kawada, K. Naoki, D.B. Costa, S.S. Kobayashi, T. Betsuyaku, K. Soejima, In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer, Oncotarget. 6 (2015). doi:10.18632\/oncotarget.5887.","DOI":"10.18632\/oncotarget.5887"},{"key":"10.1016\/j.lungcan.2022.06.012_b0070","doi-asserted-by":"crossref","unstructured":"J.C.H. Yang, M.J. Ahn, D.W. Kim, S.S. Ramalingam, L. v. Sequist, W.C. Su, S.W. Kim, J.H. Kim, D. Planchard, E. Felip, F. Blackhall, D. Haggstrom, K. Yoh, S. Novello, K. Gold, T. Hirashima, C.C. Lin, H. Mann, M. Cantarini, S. Ghiorghiu, P.A. J\u00e4nne, Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component, Journal of Clinical Oncology. 35 (2017) 1288\u20131296. doi:10.1200\/JCO.2016.70.3223.","DOI":"10.1200\/JCO.2016.70.3223"},{"key":"10.1016\/j.lungcan.2022.06.012_b0075","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2022.06.012_b0080","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M\u2013Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2022.06.012_b0085","doi-asserted-by":"crossref","unstructured":"V. Gregorc, C. Lazzari, N. Karachaliou, R. Rosell, M. Santarpia, Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer, Translational Lung Cancer Research. 7 (2018) S165\u2013S170. doi:10.21037\/tlcr.2018.03.19.","DOI":"10.21037\/tlcr.2018.03.19"},{"key":"10.1016\/j.lungcan.2022.06.012_b0090","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/annonc\/mdx820","article-title":"CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two phase II trials","volume":"29","author":"Goss","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.06.012_b0095","article-title":"1529P - Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)","volume":"30","author":"Kim","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2022.06.012_b0100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.lungcan.2020.11.027","article-title":"Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations","volume":"152","author":"Yang","year":"2021","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2022.06.012_b0105","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-019-5820-0","article-title":"EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer","volume":"19","author":"Fang","year":"2019","journal-title":"BMC Cancer."},{"key":"10.1016\/j.lungcan.2022.06.012_b0110","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.lungcan.2021.10.006","article-title":"A phase I\/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer","volume":"162","author":"Yasuda","year":"2021","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2022.06.012_b0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2019.12.013","article-title":"van der Wekken, A.J. de Langen, Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer","volume":"141","author":"van Veggel","year":"2020","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2022.06.012_b0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.lungcan.2020.11.027","article-title":"Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse <em>EGFR<\/em> exon 20 insertion mutations","volume":"152","author":"Yang","year":"2021","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2022.06.012_b0125","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00280-016-2992-z","article-title":"Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: Implications for formulation, dose, and dosing frequency in pivotal clinical studies","volume":"77","author":"Planchard","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2022.06.012_b0130","doi-asserted-by":"crossref","unstructured":"Z. Piotrowska, Y. Wang, L. v Sequist, S.S. Ramalingam, ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions., Journal of Clinical Oncology. 38 (2020) 9513. doi:10.1200\/JCO.2020.38.15_suppl.9513.","DOI":"10.1200\/JCO.2020.38.15_suppl.9513"},{"key":"10.1016\/j.lungcan.2022.06.012_b0135","doi-asserted-by":"crossref","unstructured":"World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects, JAMA - Journal of the American Medical Association. 310 (2013) 2191\u20132194. doi:10.1001\/jama.2013.281053.","DOI":"10.1001\/jama.2013.281053"},{"key":"10.1016\/j.lungcan.2022.06.012_b0140","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2022.06.012_b0145","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), n.d. http:\/\/www.meddramsso.com."},{"key":"10.1016\/j.lungcan.2022.06.012_b0150","doi-asserted-by":"crossref","unstructured":"G.J. Riely, J.W. Neal, D.R. Camidge, A.I. Spira, Z. Piotrowska, D.B. Costa, A.S. Tsao, J.D. Patel, S.M. Gadgeel, L. Bazhenova, V.W. Zhu, H.L. West, T. Mekhail, R.D. Gentzler, D. Nguyen, S. Vincent, S. Zhang, J. Lin, V. Bunn, S. Jin, S. Li, P.A. J\u00e4nne, Activity and safety of mobocertinib (Tak-788) in previously treated non\u2013small cell lung cancer with egfr exon 20 insertion mutations from a phase i\/ii trial, Cancer Discovery. 11 (2021) 1688\u20131699. doi:10.1158\/2159-8290.CD-20-1598.","DOI":"10.1158\/2159-8290.CD-20-1598"},{"key":"10.1016\/j.lungcan.2022.06.012_b0155","doi-asserted-by":"crossref","unstructured":"J.P. Robichaux, Y.Y. Elamin, Z. Tan, B.W. Carter, S. Zhang, S. Liu, S. Li, T. Chen, A. Poteete, A. Estrada-Bernal, A.T. Le, A. Truini, M.B. Nilsson, H. Sun, E. Roarty, S.B. Goldberg, J.R. Brahmer, M. Altan, C. Lu, V. Papadimitrakopoulou, K. Politi, R.C. Doebele, K.K. Wong, J. v. Heymach, Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer, Nature Medicine. 24 (2018) 638\u2013646. doi:10.1038\/s41591-018-0007-9.","DOI":"10.1038\/s41591-018-0007-9"},{"key":"10.1016\/j.lungcan.2022.06.012_b0160","doi-asserted-by":"crossref","first-page":"9514","DOI":"10.1200\/JCO.2020.38.15_suppl.9514","article-title":"Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients","volume":"38","author":"Le","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.06.012_b0165","doi-asserted-by":"crossref","first-page":"9014","DOI":"10.1200\/JCO.2021.39.15_suppl.9014","article-title":"Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1\/2 study","volume":"39","author":"Ramalingam","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.06.012_b0170","unstructured":"FDA Approves Mobocertinib for EGFR Exon 20 Insertion+ NSCLC, U.S. Food & Drug Administration. (2021)."},{"key":"10.1016\/j.lungcan.2022.06.012_b0175","doi-asserted-by":"crossref","unstructured":"K. Park, E.B. Haura, N.B. Leighl, P. Mitchell, C.A. Shu, N. Girard, ; Santiago Viteri, J.-Y. Han, ; Sang-We Kim, ; Chee, K. Lee, J.K. Sabari, ; Alexander, I. Spira, ; Tsung-Ying Yang, ; Dong-Wan Kim, ; Ki, H. Lee, R.E. Sanborn, J. Jo\u015b, J. Trigo, ; Koichi Goto, J.-S. Lee, ; James, C.-H. Yang, ; Ramaswamy Govindan, J.M. Bauml, ; Pilar Garrido, ; Matthew, G. Krebs, K.L. Reckamp, ; John Xie, J.C. Curtin, ; Nahor Haddish-Berhane, A. Roshak, D. Millington, P. Lorenzini, ; Meena Thayu, ; Roland, E. Knoblauch, B.C. Cho, Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study, J Clin Oncol. 39 (2021) 3391\u20133402. doi:10.1200\/JCO.21.","DOI":"10.1200\/JCO.21.00662"},{"key":"10.1016\/j.lungcan.2022.06.012_b0180","unstructured":"Committee for Medicinal Products for Human Use (CHMP): 8-11 November 2021, (2021). https:\/\/www.ema.europa.eu\/en\/events\/committee-medicinal-products-human-use-chmp-8-11-november-2021 (accessed December 24, 2021)."},{"key":"10.1016\/j.lungcan.2022.06.012_b0185","unstructured":"FDA grants accelerated approval to amivantamab-vmjw for metastatic non-small cell lung cancer, U.S. Food & Drug Administration. (2021). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-amivantamab-vmjw-metastatic-non-small-cell-lung-cancer (accessed December 24, 2021)."},{"key":"10.1016\/j.lungcan.2022.06.012_b0205","doi-asserted-by":"crossref","unstructured":"H. Udagawa, S. Hasako, A. Ohashi, R. Fujioka, Y. Hakozaki, M. Shibuya, N. Abe, T. Komori, T. Haruma, M. Terasaka, R. Fujita, A. Hashimoto, K. Funabashi, H. Yasuda, K. Miyadera, K. Goto, D.B. Costa, S.S. Kobayashi, TAS6417\/CLN-081 is a pan-mutation-selective EGFR tyrosine kinase inhibitor with a broad spectrum of preclinical activity against clinically relevant EGFR mutations, Molecular Cancer Research. 17 (2019) 2233\u20132243. doi:10.1158\/1541-7786.MCR-19-0419.","DOI":"10.1158\/1541-7786.MCR-19-0419"},{"key":"10.1016\/j.lungcan.2022.06.012_b0210","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1200\/JCO.2021.39.15_suppl.9077","article-title":"Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20)","volume":"39","author":"Piotrowska","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.06.012_b0215","unstructured":"FDA Grants Breakthrough Therapy Designation to CLN-081 for Locally Advanced\/Metastatic EGFR Exon 20\u2013Mutant NSCLC, U.S. Food & Drug Administration. (2022)."},{"key":"10.1016\/j.lungcan.2022.06.012_b0220","unstructured":"Dizal Pharmaceutical Co. Ltd., FDA grants breakthrough therapy designation for dizal pharmaceutical\u2019s DZD9008 in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon20 insertion., (2022)."},{"key":"10.1016\/j.lungcan.2022.06.012_b0225","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1200\/JCO.2021.39.15_suppl.9008","article-title":"Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations","volume":"39","author":"Yang","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2022.06.012_b0230","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2022.06.012_b0235","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123561","article-title":"Egfr-d770>gy and other rare egfr exon 20 insertion mutations with a g770 equivalence are sensitive to dacomitinib or afatinib and responsive to egfr exon 20 insertion mutant-active inhibitors in preclinical models and clinical scenarios","volume":"10","author":"Kobayashi","year":"2021","journal-title":"Cells."},{"key":"10.1016\/j.lungcan.2022.06.012_b0240","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/onco.13537","article-title":"Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations","volume":"26","author":"Sehgal","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2022.06.012_b0245","article-title":"Phase II study of osimertinib in NSCLC patients with EGFR exon 20 insertion mutation: A multicenter trial of the Korean Cancer Study Group (LU17-19)","volume":"30","author":"Kim","year":"2019","journal-title":"Ann. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222005347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500222005347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:02:41Z","timestamp":1759237361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500222005347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":46,"alternative-id":["S0169500222005347"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.06.012","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2022.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}